Emerging viral infections

Current Opinion in Infectious Diseases

Volumn 14, Issue 4, 2001, Pages 467-480

  Lee, Laura M ^a   Henderson, David K ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SPONGIFORM ENCEPHALOPATHY; CREUTZFELDT JAKOB DISEASE; EBOLA VIRUS; HANTAVIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICINE; REVIEW; VIRUS INFECTION; VIRUS TRANSMISSION; WEST NILE FLAVIVIRUS;

EID: 0034913129     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200108000-00012     Document Type: Review

References (184)

1. The global epidemiology of HIV/AIDS
2. Human immunodeficiency virus: An epidemic without precedent
3. Tracking the HIV epidemic: Current issues, future challenges
4. HIV in pregnancy: Strategies for management
5. HIV and AIDS in adolescents
6. Epidemiology of HIV/AIDS in children
7. Risky sexual behavior among adolescent women
8. Microbial corruption of the chemokine system: An expanding paradigm
9. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS
10. HIV co-receptors solve old questions and raise many new ones
11. Benchmarks for antiretroviral therapy
12. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine
13. Restoration of the immune system with anti-retroviral therapy
14. Immunological effects of antiretroviral therapy
15. T cell regeneration in HIV-infected subjects under highly active antiretroviral therapy
16. Immune reconstitution in HIV infection
17. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
18. Prevention Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures: Worldwide, 1997-2000
19. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues
20. Mitochondrial toxicity of antiviral drugs
21. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
22. Current strategies in the treatment of HIV infection
23. Limits to potent antiretroviral therapy
24. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
25. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
26. Prophylaxis against opportunistic infections in patients with human immunodeficiency virus infection
27. The epidemiology of acquired immunodeficiency syndrome malignancies
28. Modulation of cellular and viral gene expression by the latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus
29. + T cells: Implications for the development of therapeutic strategies
30. Chemokines, cytokines and HIV: A complex network of interactions that influence HIV pathogenesis
31. Immune control of HIV-1 after early treatment of acute infection
32. Containing HIV after infection
33. The role of skin dendritic cells in the initiation of human immunodeficiency virus infection
34. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques
35. Chemoprevention of retroviral infection: Success is determined by virus inoculum strength and cellular immunity
36. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission
37. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood
38. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
39. Transient detection of plasma HIV-1 RNA during postexposure prophylaxis
40. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
41. Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens
42. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
43. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
44. Antibodies and resistance to natural HIV infection
45. + lymphocytes
46. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
47. Effects of in vivo CD8(+) T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine
48. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
49. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine
50. HIV postexposure prophylaxis in the 21st century
51. Risk and management of blood-borne infections in health care workers
52. Prevention of SlV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine
53. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SlVmne infection depends critically on timing of initiation and duration of treatment
54. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005
55. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus
56. Impact of zidovudine post-perinatal exposure prophylaxis on vertical HIV-1 transmission: A prospective cohort study in four US cities [abstract]. In: Prevention and Treatment of HIV Infection in Infants and Children (Global Strategies for the Prevention of HIV Transmission from Mothers to Infants); September 1-5 1999; Montreal, Canada
57. The CDC Needlestick Surveillance Group. A case-control study of HIV seroconversion in health care workers after percutaneous exposure
58. Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis
59. Pathogenesis, natural history, treatment, and prevention of hepatitis C
60. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
61. + T cells with viral clearance in acute hepatitis C
62. Interaction between the hepatitis C virus and the immune system
63. Cell mediated immune response to the hepatitis C virus
64. Hepatitis C virus and its pathogenesis
65. 45-year follow-up of hepatitis C virus infection in healthy young adults
66. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study
67. Antiviral therapy for patients with chronic hepatitis C
68. Hepatitis B and hepatitis C in emergency department patients
69. Sharing of drug preparation equipment as a risk factor for hepatitis C
70. Hepatitis C
71. National Institutes of Health National Institutes of Health Consensus Development Conference Panel statement management of hepatitis C
72. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group
73. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
74. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group
75. Pathogenesis, diagnosis and management of hepatitis C
76. Current therapy for chronic hepatitis C
77. Novel approaches to the treatment of hepatitis C virus infection
78. Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets
79. Advances in the treatment of hepatitis C
80. Treatment of chronic hepatitis C virus infection
81. Hantaviruses
82. Emerging viral diseases
83. Hantavirus pulmonary syndrome outbreak in Argentina: Molecular evidence for person-to-person transmission of Andes virus
84. Persistent hantavirus infections: Characteristics and mechanisms
85. Hantavirus pulmonary syndrome: A clinical description of 17 patients with a newly recognized disease
86. Outbreak of hantavirus infection in the Four Corners region of the United States in the wake of the 1997-1998 El Niño-southern oscillation
87. Cellular receptors and hantavirus pathogenesis
88. Humoral immune responses in the hantavirus cardiopulmonary syndrome
89. Sin nombre virus (SNV) Ig isotype antibody response during acute and convalescent phases of hantavirus pulmonary syndrome
90. Hemorrhagic fever with renal syndrome in the Dolenjska region of Slovenia: A 10-year survey
91. Variant Creutzfeldt Jakob disease
92. New variant Creutzfeldt-Jakob disease
93. Variant Creutzfeldt-Jakob disease in UK children: A national surveillance study
94. Pathology of variant Creutzfeldt-Jakob disease
95. The relationship between new variant Creutzfeldt-Jakob disease and bovine spongiform encephalopathy
96. Bovine spongiform encephalopathy: Epidemiological studies
97. Temporal aspects of the epidemic of bovine spongiform encephalopathy in Great Britain: Individual animal-associated risk factors for the disease
98. Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans
99. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease: Background, evolution, and current concerns
100. Incidence of variant Creutzfeldt-Jakob disease in the UK
101. Transmission of BSE by blood transfusion in sheep
102. Transmission of BSE by blood transfusion
103. BSE and transmission through blood
104. How is Creutzfeldt-Jakob disease acquired?
105. Update: West Nile-like viral encephalitis: New York, 1999
106. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States
107. West Nile virus in the New World: Appearance, persistence, and adaptation to a new econiche: An opportunity taken
108. Emergence of West Nile Virus Encephalitis in the New York Metropolitan Area
109. Migratory birds and spread of West Nile virus in the Western Hemisphere
110. Emerging arboviral encephalitis. Newsworthy in the West but much more common in the East
111. West Nile encephalitis epidemic in southeastern Romania
112. Rhombencephalitis caused by West Nile fever virus
113. West Nile fever heads north
114. Lessons from the West Nile viral encephalitis outbreak in New York City, 1999: Implications for bioterrorism preparedness
115. West Nile virus in the United States guidelines for detection, prevention, and control
116. Outbreak not contained. West Nile virus triggers a reevaluation of public health surveillance
117. Infections by viruses of the families Bunyaviridae and Filoviridae
118. An introduction to Ebola: The virus and the disease
119. Marburg and Ebola viruses
120. Symptomless infection with Ebola virus
121. Risks and prevention of nosocomial transmission of rare zoonotic diseases
122. Surviving Ebola virus infection
123. Human asymptomatic Ebola infection and strong inflammatory response
124. Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients
125. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis
126. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury
127. Epitopes involved in antibody-mediated protection from Ebola virus
128. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein
129. Development of a preventive vaccine for Ebola virus infection in primates
130. Processing of the Ebola virus glycoprotein by the proprotein convertase furin
131. Oldest description of roseola and implications for the antiquity of human herpesvirus 6
132. Prospective study of persistence and excretion of human herpesvirus-6 in patients with exanthem subitum and their parents
133. The spectrum of human herpesvirus 6 infection: From roseola infantum to adult disease
134. Human herpesvirus-6 and -7 infections in children: Agents of roseola and other syndromes
135. HHV-6, 7 and their related diseases
136. HHV-6 and HHV-7 as exogenous agents in human lymphocytes
137. Human herpesvirus 6
138. Early diagnosis of primary human herpesvirus 6 infection in childhood: Serology, polymerase chain reaction, and virus load
139. Human herpesvirus 6: An emerging pathogen
140. Acute disseminated demyelination due to primary human herpesvirus-6 infection
141. Reactivation of human herpesvirus 6 by infection of human herpesvirus 7
142. Human herpesviruses 6 and 7: Identification of newly recognized viral pathogens and their association with human disease
143. Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): Epidemiology and pathogenesis
144. Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus
145. Intrafamilial transmission of human herpesvirus 8
146. Serological and virological evidence of non-sexual transmission of human herpesvirus type 8 (HHVS)
147. Kaposi's sarcoma associated with previous human herpesvirus 8 infection in kidney transplant recipients
148. Human herpesvirus 8 infections
149. The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8)
150. Immunosuppression, timing of human herpesvirus 8 infection, and risk of Kaposi's sarcoma among human immunodeficiency virus type 1-infected persons and transplant recipients
151. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage
152. Human herpesvirus 8: Virology, epidemiology and related diseases
153. KSHV (HHVS) infection
154. Kaposi's sarcoma
155. Three new human herpesviruses (HHV6, 7, and 8)
156. Human herpesviruses-6, -7 and -8 in organ transplant recipients
157. Prediction of human herpesvirus 6 infection after allogeneic bone marrow transplantation
158. Subacute leukoencephalitis caused by CNS infection with human herpesvirus-6 manifesting as acute multiple sclerosis
159. Plaque-associated expression of human herpesvirus 6 in multiple sclerosis
160. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: Increased IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA
161. Tissue distribution and variant characterization of human herpesvirus (HHV)-6: Increased prevalence of HHV-6A in patients with multiple sclerosis
162. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients
163. HHV-6 and multiple sclerosis
164. Human herpesvirus 7
165. Neuroinvasion by human herpesvirus type 7 in a case of exanthem subitum with severe neurologic manifestations
166. Epidemiological study of human herpesvirus-6 and human herpesvirus-7 in pityriasis rosea
167. Human herpesvirus 7 and pityriasis rosea
168. Pityriasis rosea is not associated with human herpesvirus 7
169. Pityriasis rosea: A virus-induced skin disease? An update
170. Human beta-herpesvirus interactions in solid organ transplant recipients
171. Association of human herpesvirus 7 with cytomegalovirus disease in renal transplant recipients
172. Human herpesvirus-6 and -7 in transplantation
173. Co-infection of two beta-herpesviruses (CMV and HHV-7) as an increased risk factor for "CMV disease" in patients undergoing renal transplantation
174. Prospective study of human betaherpesviruses after renal transplantation: Association of human herpesvirus 7 and cytomegalovirus co-infection with cytomegalovirus disease and increased rejection
175. Selective activity of various antiviral compounds against HHV-7 infection
176. A prospective seroepidemiological study of human herpesvirus-8 infection and the risk of multiple myeloma
177. Bone marrow failure associated with human herpesvirus 8 infection after transplantation
178. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma
179. Human herpesvirus 8 infection occurs following adolescence in the United States
180. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population
181. Blood-borne and sexual transmission of human herpesvirus 8 in women with or at risk for human immunodeficiency virus infection
182. Human herpesvirus 8 infection and Kaposi's sarcoma among human immunodeficiency virus-infected and uninfected women
183. Human herpesvirus-8 infection among heterosexual partners of patients with classical Kaposi's sarcoma
184. Mucosal shedding of human herpesvirus 8 in men